IDNT study - description and results

age between 30 and 70 years;type 2 diabetes mellitus; hypertension (systolic blood pressure of more than 135 mm Hg while sitting, a diastolic blood pressure of more than 85 mm Hg while sitting, or documented treatment with antihypertensive agents); proteinuria, with urinary protein excretion of at least 900 mg per 24 hours; serum creatinine between 1.0 and 3.0 mg per deciliter (88 and 265 �mol per liter) in women and 1.2 and 3.0 mg per deciliter (106 and 265 �mol per liter) in men.

Baseline characteristics

baseline BP	159/87 mmHg
Female (%)	32%
Age	58.6y
prior cardiovascular disease	29%

Results

Endpoint Studied treat.
n/N Control treat.
n/N Graph RR [95% CI]

All cause death

83 / 567
93 / 569
0,90 [0,68;1,18] 0 2 1.0

Endpoint	Events (%)		Relative Risk	95% CI	Endpoint definition in the trial	Ref
Relative risks
Endpoint	Studied treat.	Control treat.	Relative Risk	95% CI	Endpoint definition in the trial	Ref
All cause death	83 / 567 (14,6%)	93 / 569 (16,3%)	0,90	[0,68;1,18]
The primary endpoint (if exists) appears in blod characters
Reference(s) used for data extraction:

Endpoint	Events rate		Absolute risk reduction (ARR)
Absolute risk reduction
Endpoint	Studied treat.	Control treat.	Absolute risk reduction (ARR)
All cause death	14,64%	16,34%	-17,1‰

Reference(s)

Trials register #

Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.. N Engl J Med 2001;345:851-60

Pubmed | Hubmed | Fulltext

IDNT study, 2001

Treatments

Patients

Method and design

Results

Reference(s)

Worth checking out